KENNEDY JOHN JED 4
4 · CONMED Corp · Filed Mar 7, 2022
Insider Transaction Report
Form 4
CONMED CorpCNMD
KENNEDY JOHN JED
VP GM GI
Transactions
- Exercise/Conversion
Common Stock
2022-03-03$59.96/sh+5,092$305,316→ 14,947 total - Sale
Common Stock
2022-03-03$144.25/sh−5,092$734,532→ 9,855 total - Sale
Common Stock
2022-03-03$144.32/sh−1,790$258,328→ 9,855 total - Exercise/Conversion
Common Stock
2022-03-03$97.69/sh+832$81,278→ 10,687 total - Sale
Common Stock
2022-03-03$144.33/sh−832$120,083→ 9,855 total - Exercise/Conversion
Options To Purchase Common Stock
2022-03-03−5,092→ 5,400 totalExercise: $59.96Exp: 2028-03-01→ Common Stock (5,092 underlying) - Exercise/Conversion
Options To Purchase Common Stock
2022-03-03−1,790→ 3,800 totalExercise: $78.76Exp: 2029-03-01→ Common Stock (1,790 underlying) - Exercise/Conversion
Options To Purchase Common Stock
2022-03-03−832→ 6,768 totalExercise: $97.69Exp: 2030-03-02→ Common Stock (832 underlying) - Exercise/Conversion
Common Stock
2022-03-03$78.76/sh+1,790$140,980→ 11,645 total
Footnotes (5)
- [F1]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.25 to $144.36. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.26 to $144.50. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.26 to $144.40. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- [F4]The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.
- [F5]The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period